EURAXI Pharma Report issue

For profit Phase 4
Founded: Tours France (1986)

Organization Overview

First Clinical Trial
2020
NCT04394481
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Euraxi Pharma | EURAXI Pharma

Active Ingredients

Drugs in Phase 4 Trials (3)

dexamethasone (1 trial)

inactivated influenza vaccine (1 trial)

ropivacaine (naropin) (1 trial)

Drugs in Other Trials (2)

bifidobacterium lactis (1 trial)

maltodextrin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Agnosia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 5